Universe Pharmaceuticals Net Income Over Time
| UPC Stock | USD 3.98 0.41 9.34% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Universe Pharmaceuticals Performance and Universe Pharmaceuticals Correlation. Will Biotechnology sector continue expanding? Could Universe diversify its offerings? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Universe Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.82) | Earnings Share (7.83) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets |
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Universe Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Universe Pharmaceuticals and related stocks such as Painreform, NKGen Biotech Common, and Elevai Labs Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRFX | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (828 K) | (1.8 M) | (4.1 M) | (7.2 M) | (8.8 M) | (9.3 M) | (14.6 M) | (13.1 M) | (12.5 M) |
| ELAB | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (784.7 K) | (1.8 M) | (4.3 M) | (6.2 M) | (5.6 M) | (5.3 M) |
| BJDX | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (1.1 M) | (3.7 M) | (9.3 M) | (10 M) | (7.7 M) | (6.9 M) | (7.3 M) |
| TIVC | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (3.6 M) | (8.5 M) | (10.1 M) | (8.2 M) | (5.7 M) | (5.1 M) | (5.3 M) |
| WINT | (2.8 M) | (21 M) | (37.3 M) | (45.2 M) | (44.1 M) | (55.2 M) | (39.5 M) | (18.4 M) | (20.5 M) | (27.5 M) | (30.3 M) | (67.6 M) | (39.2 M) | (20.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| MLEC | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (13.8 K) | (4.5 M) | (51.8 M) | (7.3 M) | (111.5 M) | (100.3 M) | (95.3 M) |
| BCTXZ | (8.6 K) | (995.7 K) | (368.7 K) | (8.9 M) | (2.7 M) | (1.7 M) | (2.6 M) | (5.4 K) | (6.2 K) | 1.4 M | (2.9 M) | (11.6 M) | (20.3 M) | (6.6 K) | (36.5 M) | (32.8 M) | (31.2 M) |
| SHPH | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (626.1 K) | (805.7 K) | (805.7 K) | (1.2 M) | (5 M) | (6.6 M) | (9.1 M) | (8.2 M) | (7.8 M) |
| NCEL | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (5.1 K) | (5.4 M) | (2.9 M) | (11.9 M) | (16.5 M) | (12.2 M) | (2 M) | (1.8 M) | (1.9 M) |
Universe Pharmaceuticals and related stocks such as Painreform, NKGen Biotech Common, and Elevai Labs Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Universe Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Universe Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Universe Pharmaceuticals | UPC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 265 Jingjiu Avenue, |
| Exchange | NASDAQ Exchange |
USD 3.98
Check out Universe Pharmaceuticals Performance and Universe Pharmaceuticals Correlation. For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Universe Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.